Biotech Values

[GrthzGd]

ECYT management made a really huge deal out of the fact that they had retained all rights to EC20, the diagnostic test they have for the folate marker. They must have mentioned this about ten times.

I don't know what a folate receptor is, but Endocyte's Pipeline page indicates that their next four drugs also target solid tumors involving those. Therefore, I would think that their EC20 test would also be used in conjunction with them, which should add to their value in shrinking certain kinds of tumors in certain kinds of patients, as it appears to have done, from Merck's perspective, in the case of EC145.